How to buy BARD1 Life Sciences shares

BARD1 Life Sciences Limited is a diagnostics & research business based in Australia. BARD1 Life Sciences shares (BD1) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. BARD1 Life Sciences has a trailing 12-month revenue of around $464,101.

How to buy shares in BARD1 Life Sciences

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for BARD1 Life Sciences. Find the share by name or ticker symbol: BD1. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BARD1 Life Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of BARD1 Life Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

US stocks

eToro Share Trading (US stocks)

Finder Award

Our top pick for

Cheap broker fees

IG Share Trading

Finder Award

Our top pick for

Long-term investing

CMC Markets Stockbroking

Finder Award

BARD1 Life Sciences share price

Compare share trading platforms

Sort by:

Name	Product	Standard brokerage fee	Inactivity fee	Markets
Superhero share trading		AUD $5	No	ASX shares, ETFs	Pay zero brokerage on all Australian ETFs. Trade ASX stocks with a flat $5 commission fee and a low minimum investment of just $100.	Go to site More Info	Compare	loading Fetching your data...
Bell Direct Share Trading Finder Award		AUD $15	No	ASX shares, mFunds, ETFs	Exclusive: New customers who open an account with Bell Direct through Finder will pay no brokerage fees on the first five stock or ETF trades until April 30, 2021 (T&Cs apply). Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.	Go to site More Info	Compare	loading Fetching your data...
IG Share Trading Finder Award		AUD $8 or 0.1%	$50 per quarter if you make fewer than three trades in that period	ASX shares, Global shares	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
CMC Markets Stockbroking Finder Award		AUD $11 or 0.1%	No	ASX shares, Global shares, mFunds, ETFs	$0 brokerage on global shares including US, UK and Japan markets. Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.	Go to site More Info	Compare	loading Fetching your data...
ANZ Share Investing		AUD 19.95	No	ASX shares, Global shares, Options trading, mFunds, ETFs, Warrants	Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments. Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.	More Info	Compare	loading Fetching your data...
Westpac Online Investing Account		AUD 19.95 or 0.11%	USD 63.50 per year on the global markets account	ASX shares, Global shares, Options trading, ETFs	More Info	Compare	loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy BARD1 Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BARD1 Life Sciences share dividends

We're not expecting BARD1 Life Sciences to pay a dividend over the next 12 months.

Have BARD1 Life Sciences's shares ever split?

BARD1 Life Sciences's shares were split on a 1:30 basis on 30 November 2020. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BARD1 Life Sciences shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for BARD1 Life Sciences shares which in turn could have impacted BARD1 Life Sciences's share price.

BARD1 Life Sciences share price volatility

Over the last 12 months, BARD1 Life Sciences's shares have ranged in value from as little as $0.57 up to $5.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while BARD1 Life Sciences's is -1.3092. This would suggest that BARD1 Life Sciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BARD1 Life Sciences has bucked the trend.

BARD1 Life Sciences overview

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.

Frequently asked questions

• What percentage of BARD1 Life Sciences is owned by insiders or institutions?

  Currently 23.395% of BARD1 Life Sciences shares are held by insiders and 13.286% by institutions.

• When does the fiscal year end for BARD1 Life Sciences?

  BARD1 Life Sciences's fiscal year ends in June.

• Where is BARD1 Life Sciences based?

  BARD1 Life Sciences's address is: 23 Normanby Road, South Perth, WA, Australia, 3168

• What is BARD1 Life Sciences's ISIN number?

  BARD1 Life Sciences's international securities identification number is: AU000000BD12